NEOPLASMS
Clinical trials for NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NEOPLASMS trials appear
Sign up with your email to follow new studies for NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug offered to lung cancer patients out of options
Disease control NO_LONGER_AVAILABLEThis program provides access to the experimental drug taletrectinib for adults with advanced ROS1-positive lung cancer who have run out of approved treatment options and cannot join regular clinical trials. The drug aims to control cancer growth in patients who have already tried…
Matched conditions: NEOPLASMS
Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Apr 01, 2026 18:10 UTC
-
First human test of experimental cancer drug begins for patients out of options
Disease control OngoingThis is the first-ever study in humans of an experimental drug called remzistotug for people with advanced solid tumors. It aims to find a safe dose and see how the body handles the drug, both alone and when combined with other cancer treatments. The trial is for patients with sp…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Early trial tests cell therapy to reboot immune system against cancer
Disease control OngoingThis early-stage study is testing a new cell-based immunotherapy called ACIT-1 in adults with cancer. The main goals are to find the safest dose and see if the treatment can help the patient's own immune system recognize and attack cancer cells. About half of the participants wil…
Matched conditions: NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Cancer Vaccines Limited • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
First human test of new cancer drug begins
Disease control OngoingThis is the first study in people to test a new cancer drug called GSK6097608. It aims to find a safe dose and see how the body handles the drug when given alone or combined with other cancer treatments. The study includes about 107 adults with advanced solid tumors that have not…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug combo tested for Tough-to-Treat cancers
Disease control OngoingThis study is testing a new drug called E7386 in combination with other cancer medications for people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The main goals are to find the safest and most effective dose and to see how well the drug combi…
Matched conditions: NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Supercharged immune cells target Hard-to-Treat cancers
Disease control OngoingThis study tests whether genetically modified immune cells can safely shrink tumors in people with advanced synovial sarcoma or liposarcoma. Researchers collect patients' own T-cells, engineer them to recognize cancer proteins, then infuse them back into the body. The trial is fo…
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Major trial tests drug combo to fight advanced uterine cancer
Disease control OngoingThis large Phase 3 study is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy helps women with advanced or recurrent endometrial cancer live longer and keeps their cancer from progressing. The trial involves 785 participants who are randomly assig…
Matched conditions: NEOPLASMS
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Modified immune cells attack rare cancers in new trial
Disease control OngoingThis study is testing a personalized cell therapy called Lete-Cel for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. Doctors take a patient's own immune cells, modify them to target a specific protein found on these cancer cells, and infuse them back. The…
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: USWM, LLC (dba US WorldMeds) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New pill targets Cancer's genetic weakness in first human trial
Disease control OngoingThis is a first-in-human study to find a safe dose and see how the body processes a new oral drug called ATV-1601. It is being tested in adults with advanced solid tumors, including certain breast cancers, that have a specific genetic change called an AKT1 E17K mutation. The main…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
First human test of new cancer pill begins
Disease control OngoingThis early-stage study is testing a new oral drug called GSK4524101, both by itself and combined with an existing cancer drug (niraparib), in adults with advanced solid tumors. The main goals are to find safe dose levels and see if the treatment can shrink tumors. It is for peopl…
Matched conditions: NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Community push aims to beat Cancer's clock in botswana
Disease control OngoingThis study is testing whether a community program called Potlako+ can help people with possible cancer symptoms get diagnosed and treated faster. The program involves educating communities about cancer warning signs and providing patient navigators to guide people through the hea…
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Supercharged immune cells target stubborn lymphoma
Disease control OngoingThis study is testing a new cell therapy for people whose Hodgkin's or Non-Hodgkin's lymphoma has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer cells, and then infuse them back into th…
Matched conditions: NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Drug trial aims to free patients from frequent throat surgeries
Disease control OngoingThis study is testing if a drug called bevacizumab can help adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants, who currently need surgery multiple times a year to clear these growths, will receive bevac…
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Supercharged immune cells take aim at tough lymphomas in groundbreaking trial
Disease control OngoingThis study is testing a new type of personalized cell therapy for adults whose CD30+ lymphomas have come back or not responded to standard treatments. Doctors take a patient's own immune cells (T cells), genetically modify them to better find and attack cancer cells, and then inf…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New Triple-Threat treatment tested for Tough-to-Treat colon cancer
Disease control OngoingThis study is testing whether a combination of three drugs (irinotecan, dabrafenib, and trametinib) plus a targeted antibody (cetuximab or panitumumab) can help control advanced colorectal cancer that has spread and carries a specific BRAF gene mutation. It is for patients whose …
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
First test of new cancer drug in humans begins
Disease control OngoingThis is a first-in-human study to test the safety and find the right dose of a new drug called GSK3745417. It is being tested alone and in combination with another cancer drug, dostarlimab, in adults with advanced solid tumors that have stopped responding to standard treatments. …
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Cancer patients get lifeline: extended access to promising drug
Disease control OngoingThis study allows patients with ALK- or RET-positive cancers who benefited from alectinib or crizotinib in previous Roche trials to continue receiving the drug after those trials end. It aims to provide ongoing treatment access while monitoring safety in about 200 participants. T…
Matched conditions: NEOPLASMS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Breathing-Tracking tech aims for pinpoint radiation in lung cancer
Disease control OngoingThis study is testing whether new technology can make radiation therapy for lung cancer more precise. It aims to adjust the radiation beam in real-time to follow a tumor's movement as a patient breathes. The research involves 20 patients to see if this tracking method is practica…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: Royal North Shore Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Engineered virus targets and kills Kids' brain cancer cells
Disease control TerminatedThis trial aimed to test an experimental virus therapy called G207 for children whose aggressive brain tumors had returned. The virus is designed to infect and kill cancer cells while sparing healthy ones. Doctors planned to inject the virus directly into the tumor and follow it …
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Real-World test for advanced lung cancer treatment combo
Disease control OngoingThis study is observing how well a combination of the drug Osimertinib and standard chemotherapy works for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) in a real-world setting. It involves 532 adult patients who have already started this specific trea…
Matched conditions: NEOPLASMS
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New weapon against advanced cancers enters human testing
Disease control OngoingThis is the first study in people to test a new immunotherapy drug called TSR-022. The main goals are to find a safe dose and see if the drug can help shrink tumors in adults with advanced cancers that have spread. The study will test TSR-022 by itself and combined with other can…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Cancer patients get lifeline to continue promising treatment
Disease control OngoingThis study allows cancer patients who were benefiting from atezolizumab treatment in previous Roche-sponsored trials to continue receiving their medication if it's not available through regular channels. The 49 participants can keep getting their treatment while researchers monit…
Matched conditions: NEOPLASMS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Experimental immune cell therapy targets Tough-to-Treat sarcomas
Disease control OngoingThis study tests an experimental treatment called Lete-Cel, which uses a patient's own genetically modified immune cells to fight two types of advanced soft tissue cancer: synovial sarcoma and myxoid/round cell liposarcoma. It involves 87 participants whose cancers have progresse…
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
First test of new Cancer-Fighting antibody begins in patients
Disease control OngoingThis is a first-in-human study to find a safe dose of a new immunotherapy drug called BI 765179 for adults with advanced solid tumors. In the first part, researchers will test the drug alone and combined with another immunotherapy (ezabenlimab). In the second part, they will test…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New cancer drug trial offers hope for patients out of options
Disease control OngoingThis is the first study in humans of an experimental immunotherapy drug called dostarlimab for people with advanced solid tumors that have stopped responding to available treatments. The main goal is to find a safe dose and schedule for the drug and to check for early signs that …
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New shot in the arm for cancer treatment?
Disease control OngoingThis study is testing a new, easier way to give the cancer drug amivantamab—as a simple injection under the skin instead of a long IV infusion. It aims to find a safe and effective dose for this new method in people with advanced solid tumors who have few other treatment options.…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
New cancer drug trial seeks to shrink advanced tumors
Disease control OngoingThis is an early-stage study testing a new immunotherapy drug called JNJ-63723283 in people with advanced cancers that have not responded to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors in cancers like lung cancer…
Matched conditions: NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC
-
New scan aims to catch breast Cancer's return sooner
Diagnosis OngoingThis study is testing if a special type of mammogram that uses a contrast dye is better at finding new or returning breast cancers in women who have already had the disease. It compares this new method to the standard mammogram to see if it finds more cancers without causing too …
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: Wendie Berg • Aim: Diagnosis
Last updated Mar 20, 2026 14:47 UTC
-
New clinic program aims to stop deadly clots in cancer patients
Prevention ENROLLING_BY_INVITATIONThis study is testing a new clinic program designed to help prevent dangerous blood clots in cancer patients who are starting treatment. It will see if training doctors and using a specific process leads to more patients being checked for clot risk and getting the right preventiv…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: University of Vermont • Aim: Prevention
Last updated Mar 23, 2026 15:18 UTC
-
Cancer survivors helping each other cope: new program tackles anxiety and depression
Symptom relief OngoingThis study is testing whether a peer-led group program can help cancer survivors manage feelings of anxiety and depression after finishing their main cancer treatment. The program involves seven weekly group sessions led by trained non-professionals, focusing on building skills t…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Mar 25, 2026 14:08 UTC
-
Teamwork exercise program aims to lift spirits and strength for cancer survivors and their caregivers
Symptom relief OngoingThis study is testing a new, culturally adapted exercise program designed for Hispanic prostate cancer survivors and the person who helps care for them. The program involves the survivor and caregiver working out together in remote group classes for three months. The main goal is…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: University of Arizona • Aim: Symptom relief
Last updated Mar 23, 2026 15:16 UTC
-
NIH opens its doors: major cancer data collection effort launches while providing standard care
Knowledge-focused ENROLLING_BY_INVITATIONThis National Cancer Institute (NCI) study provides standard cancer care and follow-up to patients who need treatment at the NIH but are not in an active research trial. It aims to collect medical information from up to 10,000 participants to help generate ideas for future cancer…
Matched conditions: NEOPLASMS
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Can better doctor training save more lung cancer patients?
Knowledge-focused OngoingThis study aims to see if providing standardized training to cancer doctors in smaller city and county hospitals leads to better testing and treatment for patients with advanced non-small cell lung cancer. It will follow 1,000 patients to measure if doctors order more recommended…
Matched conditions: NEOPLASMS
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Scientists dig through old records to map hidden dangers of promising cancer drug
Knowledge-focused OngoingThis study looks back at the medical records of 232 adults with cancer who were treated with an immunotherapy drug called M7824. The goal is to create a complete list of the side effects people experienced, including skin issues. By understanding these risks better, doctors hope …
Matched conditions: NEOPLASMS
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:18 UTC
-
Researchers dig into Real-World data on cancer Patients' blood clots
Knowledge-focused OngoingThis study looks back at existing medical records to understand how blood clots are treated in people with cancer. It aims to see which blood-thinning medications work best, what they cost, and what the outcomes are for patients. The goal is to gather knowledge to help improve fu…
Matched conditions: NEOPLASMS
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:09 UTC
-
Cancer drug safety watch: tracking Long-Term effects
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks the long-term safety of experimental cancer treatments in patients who previously participated in earlier Janssen trials. It follows 80 people with various cancers to monitor for serious side effects over time. The goal is to better understand the safety profile…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated Mar 11, 2026 14:54 UTC